Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2014 + Paclitaxel in Squamous NSCLC
NCT02403895Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of vistusertib in squamous cell carcinoma of the lung (SCCL), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate at 3 months. Started Apr 2015; status: terminated.
02
Drugs
vistusertib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02403895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403895.